Key facts
- BetaGlue Therapeutics’s last known valuation is $25.3M (Jul 2022).
- It has raised $49.0M; the latest was Later Stage VC ($8.1M) in Apr 2025.
- Notable investors include European Innovation Council, LIFTT, NEVA SGR, Panakes Partners, Enea Tech e Biomedical — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for BetaGlue Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for BetaGlue Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BetaGlue Therapeutics
Developer of a medical platform designed to provide a targeted approach in the treatment of cancer. The company offers a precision radiotherapy platform integrating radiochemistry, medical devices, and localized radiation delivery to deliver targeted treatment for solid tumor cancers, enabling oncology clinicians and healthcare providers to treat solid tumor patients with focused therapy while reducing impact on surrounding tissue.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2009
- Employees
- 24
- Website
- betaglue.com/
- Ownership
- Privately Held (backing)
BetaGlue Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BetaGlue Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BetaGlue Therapeutics in its N-PORT filings yet. We sweep new filings monthly.